Lasmiditan is Effective in the Acute Treatment of Migraine in Patients with Insufficient Response to Triptans: Findings from the Modified-parallel, Placebo-controlled, Double-blind, Phase 3 Consistency CENTURION Study

被引：0
|
作者：
Reuter, U. [1 ]
Lombard, L. [2 ]
Krege, J. [2 ]
Valderas, E. Gomez [2 ]
Krikke-Workel, J. [2 ]
Agnello, G. Dell [2 ]
Dowsett, S. [2 ]
Buse, D. C. [3 ]
机构：
[1] Charite, Dept Neurol, Berlin, Germany
[2] Eli Lilly & Co, Indianapolis, IN USA
[3] Albert Einstein Coll Med, New York, NY USA
来源：
JOURNAL OF HEADACHE AND PAIN | 2021年 / 22卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P0387
引用
收藏
页码：136 / 136
页数：1
相关论文
共 50 条
  • [31] Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study
    Bo Hu
    Gang Li
    Xiaohong Li
    Shan Wu
    Tingmin Yu
    Xiang Li
    Hongru Zhao
    Zhihua Jia
    Junpeng Zhuang
    Shengyuan Yu
    [J]. The Journal of Headache and Pain, 2022, 23
  • [32] A phase 3 placebo-controlled study of galcanezumab in patients with treatment-resistant migraine: Results from the 3-month double-blind treatment phase of the conquer study
    Mulleners, W.
    Kim, B.
    Lainez, M. J.
    Lanteri-Minet, M.
    Aurora, S. K.
    Nichols, R. M.
    Wang, S.
    Tockhorn-Heidenreich, A.
    Detke, H.
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [33] Effect of Fremanezumab on the Total Burden of Migraine in Patients with Episodic or Chronic Migraine: Findings from 3 Randomized, Double-blind, Placebo-controlled Phase 3 Studies
    Sun-Edelstein, Christina
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Barash, Steve
    Brandes, Jan Lewis
    [J]. NEUROLOGY, 2021, 96 (15)
  • [34] Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
    Takeshima, Takao
    Sakai, Fumihiko
    Hirata, Koichi
    Imai, Noboru
    Matsumori, Yasuhiko
    Yoshida, Ryuji
    Peng, Cheng
    Cheng, Sunfa
    Mikol, Daniel D.
    [J]. HEADACHE, 2021, 61 (06): : 927 - 935
  • [35] Evaluation of the efficacy of intravenous acetaminophen in the treatment of acute migraine attacks:: a double-blind, placebo-controlled parallel group multicenter study
    Leinisch, E
    Evers, S
    Kaempfe, N
    Kraemer, C
    Sostak, P
    Jürgens, T
    Straube, A
    May, A
    [J]. PAIN, 2005, 117 (03) : 396 - 400
  • [36] Ibuprofen or acetaminophen for the acute treatment of migraine in children: A double-blind, randomized, placebo-controlled, crossover study
    Hamalainen, ML
    Hoppu, K
    Valkeila, E
    Santavuori, P
    [J]. NEUROLOGY, 1997, 48 (01) : 103 - 107
  • [37] A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents
    Winner, P
    Rothner, AD
    Saper, J
    Nett, R
    Asgharnejad, M
    Laurenza, A
    Austin, R
    Peykamian, M
    [J]. PEDIATRICS, 2000, 106 (05) : 989 - 997
  • [38] Rizatriptan 5 mg for the acute treatment of migraine in adolescents: A randomized, double-blind, placebo-controlled study
    Winner, P
    Lewis, D
    Visser, WH
    Jiang, KH
    Ahrens, S
    Evans, JK
    [J]. HEADACHE, 2002, 42 (01): : 49 - 55
  • [39] Ubrogepant for the acute treatment of migraine when administred during the prodrome: Results from a phase 3, randomized, double-blind, placebo-controlled, crossover study
    Dodick, David
    Goadsby, Peter
    Schwedt, Todd
    Lipton, Richard
    Davidovic, Goran
    Liu, Chengcheng
    Lu, Kaifeng
    Yun, Yu Sung
    Severt, Lawrence
    Finnegan, Michelle
    Trugman, Joel
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 455
  • [40] Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial
    Jiying Zhou
    Guogang Luo
    Yuming Xu
    Xiaosu Yang
    Xiaoping Pan
    Zhao Dong
    Shiying Zhong
    Hui Liu
    Fei Ji
    Shengyuan Yu
    [J]. Advances in Therapy, 2022, 39 : 5229 - 5243
12345